细胞色素P450 SNP与冠心病易感性关系的研究进展

doi:10.12092/j.issn.1009-2501.2018.04.019

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (4): 477-480.doi: 10.12092/j.issn.1009-2501.2018.04.019

• 综述与讲座 • 上一篇

细胞色素P450 SNP与冠心病易感性关系的研究进展

彭秋菊^1,2，严华成¹，石磊¹

¹广州军区广州总医院药学部，广州 510010，广东；²广东药科大学药学院，广州 510006，广东

收稿日期:2017-08-30 修回日期:2017-09-27 出版日期:2018-04-26 发布日期:2018-04-13
通讯作者: 石磊，女，硕士，主任药师，硕士生导师，研究方向：遗传药理学和药代动力学。 Tel：020-88653436 E-mail：lucyshi622._921@163.com
作者简介:彭秋菊，女，硕士研究生，研究方向：遗传药理学。 Tel：18826402710 E-mail：424580810@qq.com
基金资助:
广东省重大科技专项(2013A022100035)

Advances in the relationship between cytochrome P450 SNP and susceptibility to coronary heart disease

PENG Qiuju ^1,2, YAN Huacheng¹, SHI Lei ¹

¹ Department of Pharmacy, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou 510010, Guangdong,China; ²College of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, Guangdong, China

Received:2017-08-30 Revised:2017-09-27 Online:2018-04-26 Published:2018-04-13

摘要/Abstract

摘要：

冠心病是一种由遗传和环境共同作用引起的复杂性疾病。大量研究表明细胞色素P450（CYP）代谢物如环氧二十碳三烯酸（EETs）、20-羟基二十碳四烯酸（20-HETE）和性激素在维持心血管功能稳态中起重要作用。在体内，CYP2C19和CYP2J2可催化花生四烯酸代谢生成EETs；CYP4F2和CYP1A1是20-HETE生成的主要合成酶； CYP17A1和CYP19是性激素合成的重要酶。因此，上述CYP基因的多态性很有可能通过影响其代谢产物的生成进而影响冠心病的发生。本文对近5年CYP基因多态性与冠心病易感性关联研究作一综述，以期为冠心病个体化防治提供参考。

关键词: 冠心病, 基因多态性, 细胞色素P450, 易感性

Abstract:

Coronary heart disease (CHD) is caused by genetic environmental interaction. Studies have shown that cytochrome P450 (CYP) metabolites such as epoxyeicosatrienoic acids (EETs), 20-hydroxy-eicosatetraenoic acid (20-HETE) and sex hormones play important roles in maintaining cardiovascular homeostasis. In vivo, CYP2C19 and CYP2J2 catalyze the metabolism of arachidonic acid (AA) to EETs; CYP4F2 and CYP1A1 are the main synthetases of 20-HETE; CYP17A1 and CYP19 are important synthetases of sex hormones. Therefore, polymorphism of the above CYP genes is likely to affect the development of CHD by influencing the production of its metabolites. This article reviews the five years' advances in the relationship between cytochrome P450 SNP and susceptibility to coronary heart disease so as to provide referential ideas for the personalized treatment of CHD.

Key words: coronary heart disease, polymorphism, cytochrome P450, susceptibility

中图分类号:

R541.4

彭秋菊，严华成，石磊. 细胞色素P450 SNP与冠心病易感性关系的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(4): 477-480.

PENG Qiuju, YAN Huacheng, SHI Lei. Advances in the relationship between cytochrome P450 SNP and susceptibility to coronary heart disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 477-480.

参考文献

［1］Spiecker M, Darius H, Hankeln T, et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2［J］. Circulation, 2004, 110(15): 2132-2136.
［2］Tzveova R, Naydenova G, Yaneva T, et al. Gender-specific effect of CYP2C8*3 on the risk of essential hypertension in Bulgarian patients［J］. Biochem Genet., 2015, 53(11-12): 319-333.
［3］Kumar ASA, Kumar SS, Umamaheswaran G, et al. Association of CYP2C8, CYP2C9 and CYP2J2 gene polymorphisms with myocardial infarction in South Indian population［J］. Pharmacol Rep, 2015, 67(1): 97-101.
［4］Xu Y, Ding H, Peng J, et al. Association between polymorphisms of CYP2J2 and EPHX2 genes and risk of coronary artery disease［J］. Pharmacogenet Genomics, 2011, 21(8): 489-494.
［5］Xia XL,Fa BT,Cong S,et al.Research/review: Insights into the mutation-induced dysfunction of arachidonic acid metabolism from modeling of human CYP2J2［J］.Curr Drug Metab,2014, 5(5):502-513.
［6］Zhu Q, Fu Z, Ma Y, et al. A novel polymorphism of the CYP2J2 gene is associated with coronary artery disease in Uygur population in China［J］. Clin Biochem, 2013, 46(12): 1047-1054.
［7］Hokimoto S, Tabata N, Akasaka T, et al. Gender differences in impact of CYP2C19 polymorphism on development of coronary artery disease［J］. J Cardiovasc Pharmacol, 2015, 65(2): 148-152.
［8］张立国, 喻卓. CYP2C19基因多态性与云南汉族人群冠心病的相关性研究［J］. 中西医结合心脑血管病杂志, 2016, 14(14):1597-1600.
［9］Polonikov A, Kharchenko A, Bykanova M, et al. Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population［J］. Gene, 2017, 627(1):451-459.
［10］李园园, 章政, 贾秀娟,等. 细胞色素P450 2C19+681G/A多态性与冠心病发病年龄的相关性［J］. 临床心血管病杂志, 2015,31(7):739-741.
［11］Ye H,Zhou A,Hong Q,et al.Association of seven thrombotic pathway gene CpG-SNPs with coronary heart disease［J］.Biomed Pharmacother,2015,72:98-102.
［12］Cheng J, Edin ML, Hoopes SL, et al. Vascular characterization of mice with endothelial expression of cytochrome P450 4F2［J］. The FASEB Journal, 2014, 28(7): 2915-2931.
［13］Stec DE,Roman RJ,Flasch A,et al.Functional polymorphism in human CYP4F2 decreases 20-HETE production［J］.Physiol Genomics,2007,30(1):74-81.
［14］Yu C, Yan Q, Fu C, et al. CYP4F2 genetic polymorphisms are associated with coronary heart disease in a Chinese population［J］. Lipids Health Dis, 2014, 13(1): 1-5.
［15］Yang H, Fu Z, Ma Y. A novel polymorphism of the CYP4F2 gene is associated with acute coronary syndrome［J］. Heart, 2012, 98(Suppl 2): E194.
［16］赵平, 常培叶, 南景龙,等. CYP4F2基因多态性与蒙古族冠心病的相关性研究［J］. 心血管康复医学杂志, 2016(1):18-21.
［17］Taspinar M, Aydos S, Sakiragaoglu O, et al. Impact of genetic variations of the CYP1A1, GSTT1, and GSTM1 genes on the risk of coronary artery disease［J］. DNA Cell Biol, 2012, 31(2): 211-218.
［18］Zhang X, Lv S, Guo C, et al. Gene-gene interaction between PPARG and CYP1A1 gene on coronary artery disease in the Chinese Han population［J］. Oncotarget, 2017, 8(21): 34398-34404.
［19］Lakshmi SVV, Naushad SM, Saumya K, et al. Role of CYP1A1 haplotypes in modulating susceptibility to coronary artery disease［J］. Indian J Biochem Biophys, 2012, 49(5):349-355.
［20］Zhang J, Wang Y, Liu Y, et al. Lack of association between CYP1A1 T6235C polymorphism and coronary artery disease: Evidence from a meta-analysis［J］. Mol Med Rep, 2013, 7(2): 543-548.
［21］Zou JG, Ma YT, Xie X, et al. The association between CYP1A1 genetic polymorphisms and coronary artery disease in the Uygur and Han of China［J］. Lipids Health Dis, 2014, 13(1): 1-12.
［22］Schunkert H, Knig IR, Kathiresan S, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease［J］. Nat Genet, 2011, 43(4): 333-338.
［23］Dichgans M, Malik R, Knig IR, et al. Shared genetic susceptibility to ischemic stroke and coronary artery disease［J］. Stroke, 2014, 45(1): 24-36.
［24］Huang EW, Peng LY, Zheng JX, et al. Investigation of associations between ten polymorphisms and the risk of coronary artery disease in Southern Han Chinese［J］. J Hum Genet, 2016, 61(5): 389-393.
［25］Dai CF, Xie X, Yang YN, et al. Relationship between CYP17A1 genetic polymorphism and coronary artery disease in a Chinese Han population［J］. Lipids Health Dis, 2015, 14(1): 1-10.
［26］ Dai CF, Xie X, Ma YT, et al. Haplotype analyses of CYP17A1 genetic polymorphisms and coronary artery disease in a Uygur population［J］. J Renin Angiotensin Aldosterone Syst, 2015, 16(2): 389-398.
［27］Wang B, Fu ZY, Ma YT, et al. Identification of a CYP19 gene single-nucleotide polymorphism associated with a reduced risk of coronary heart disease［J］. Genet Test Mol Biomarkers, 2016, 20(1): 2-10.
［28］Bampali K, Grassos C, Mouzarou A, et al. Genetic variant in the CYP19A1 gene associated with coronary artery disease［J］. Genet Res Int, 2015, 2015:1-5.

[1]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[2]	朱丽, 魏兵, 廖世峨, 张超, 郑晓宇, 刘亚军. 药物代谢酶细胞色素P450单核苷酸多态性影响哮喘儿童吸入皮质醇激素疗效研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 536-543.
[3]	张志英, 靳秀红, 张小宁, 张向峰, 罗青林, 张松林. TBX21和ADCY9多态性在儿童哮喘发生发展中的临床研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 407-412.
[4]	刘璐, 石雨菲, 何庆烽, 徐凤艳, 王鲲, 蔡卫民, 相小强. 群体模型分析方法评估基因多态性对药物PK/PD的影响[J]. 中国临床药理学与治疗学, 2023, 28(11): 1275-1282.
[5]	王爽, 刘嘉, 张月丽. POR*28基因多态性与中国肾移植患者他克莫司稳定剂量的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(9): 991-997.
[6]	付虹, 田磊. 缺血性脑卒中伴高血压病患者个体化精准治疗的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 870-876.
[7]	陈文刚, 殷勤, 张巍巍, 周露露, 寇婉青, 袁小龙. 皖南地区高血压患者MTHFR基因多态性分布及与血Hcy相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 768-774.
[8]	武元竹, 刘俊, 杨魁, 彭静, 栾家杰, 韦俊, 张大发, 宋帅, 袁小龙, 王中方, 张年宝, 解丹, 姜鹏, 范洁. 安徽地区汉族人群CYP2C9*3和VKORC1-1639G>A基因多态性分布及对华法林稳定剂量的影响[J]. 中国临床药理学与治疗学, 2022, 27(6): 652-659.
[9]	王琦, 邹云增. 冠心病降脂治疗新进展——Evinacumab[J]. 中国临床药理学与治疗学, 2022, 27(4): 362-364.
[10]	王琦, 邹云增. 冠心病降脂治疗新进展——Inclisiran[J]. 中国临床药理学与治疗学, 2022, 27(4): 365-368.
[11]	王琦, 邹云增. 冠心病降脂治疗新进展——贝派地酸[J]. 中国临床药理学与治疗学, 2022, 27(4): 369-372.
[12]	常书福. 冠心病药物治疗进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 405-408.
[13]	王瑞杰, 王亮, 徐丹, 周淼淼, 李纪明. PCSK9抑制剂对冠心病患者血脂及炎症因子的影响[J]. 中国临床药理学与治疗学, 2022, 27(4): 409-417.
[14]	陈佳音, 王丽, 王立军, 童刚领, 马洁, 陈西敬, 卢杨. 有机阳离子转运体基因多态性与奥沙利铂毒性及疗效的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(2): 171-177.
[15]	闫磊, 蒋海彬, 娜菲莎·帕尔哈提, 热孜宛古丽·伊克木, 耿博宇, 麦尔哈巴·麦麦提艾力. 不同剂量右美托咪定对冠心病患者非心脏手术应激及术后睡眠影响[J]. 中国临床药理学与治疗学, 2022, 27(12): 1340-1346.

细胞色素P450 SNP与冠心病易感性关系的研究进展

Advances in the relationship between cytochrome P450 SNP and susceptibility to coronary heart disease

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价